At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Cabozantinib +1 moredrug
Likely dose
Cabozantinib 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)
In Brief
A Phase 2 clinical trial evaluating Cabozantinib and Pembrolizumab for Metastatic Urothelial Carcinoma and Bladder Cancer. Completed, enrolled 37 participants across 3 sites.
Detailed Summary
This is an open label, non-randomized phase 2 study of the combination of pembrolizumab and cabozantinib to assess overall response rate (ORR), progression free survival at 6 months (PFS6), and overall survival (OS) in patients with metastatic urothelial carcinoma (UC) ineligible for cisplatin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Urothelial Carcinoma, Bladder Cancer
CountriesUnited States
CollaboratorsExelixis
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartSep 2018
Primary CompletionAug 2023
Study CompletionApr 2024
TodayJul 2026
First PostedMay 23, 2018
Enrollment StartSep 18, 2018
Primary CompletionAug 2, 2023
Study CompletionApr 15, 2024
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 8.1 years ago
Interventions
Cabozantinibdrug
Cabozantinib is administered at 40 mg oral daily
Pembrolizumabdrug
Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks.